In re HIV Antitrust Litigation
Case Number:
3:19-cv-02573
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Baron & Budd
- Berry Silberberg
- Boies Schiller
- Cahill Gordon
- Crowell & Moring
- Dillingham & Murphy
- Duane Morris
- Faegre Drinker
- Glancy Prongay
- Goodwin Procter
- Hagens Berman
- Hangley Aronchick
- Hausfeld LLP
- Hilliard & Shadowen
- Holland & Knight
- Kanner & Whiteley
- Kellogg Hansen
- Kenny Nachwalter
- Kessler Topaz
- Kirkland & Ellis
- Law Offices of Francis O. Scarpulla
- Lockridge Grindal
- Milberg Coleman
- Miller Shah LLP
- Morrison Foerster
- NastLaw
- Nixon Peabody
- Nussbaum Law Group
- Pritzker Levine
- Proskauer Rose
- Radice Law Firm
- Rivero Mestre
- Robins Kaplan
- Spector Roseman
- Sperling & Slater
- Whatley Kallas
- White & Case
- Wilson Sonsini
- Zelle LLP
Companies
- Aetna Inc.
- Akros Pharma Inc.
- Albertsons Cos. Inc.
- Amneal Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- BlueCross BlueShield of South Carolina
- Bristol-Myers Squibb Co.
- Centene Corp.
- Cipla Ltd.
- CVS Health Corp.
- Florida Blue
- Fraternal Order of Police
- Gilead Sciences Inc.
- Health Care Service Corp.
- Humana Inc.
- Japan Tobacco
- Johnson & Johnson
- LifeWallet
- Mylan NV
- Rite Aid Corp.
- Service Employees International Union
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
- Zydus Pharmaceuticals Inc.
Government Agencies
Sectors & Industries:
-
June 13, 2023
Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told
A retired Harvard Medical School health economics professor testified Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal over two HIV medications, saying the agreement "delayed competition and imposed massive harms on purchasers," costing them over $2 billion.
-
June 09, 2023
Gilead-Teva IP Deal Struck Despite Invalidity Issues, Jury Told
Two experts took the stand Friday on behalf of indirect drug buyers in a California federal antitrust trial over claims Teva struck an illegal "pay for delay" patent deal with Gilead over two HIV medications, testifying that Gilead's patents covered obvious technology and Teva knew that before entering the deal.
-
June 07, 2023
Teva Atty Says Gilead Deal Followed Bad News On FDA Filing
A top Teva lawyer testified Wednesday in an antitrust trial over claims that the company struck an illegal "pay for delay" deal with Gilead over two HIV medications, saying Teva reached the mid-trial settlement just days after learning the FDA was unlikely to give it first-filer rights to exclusively sell its generic versions.
-
June 06, 2023
Ex-Gilead GC Says He Didn't Calculate Teva's Gain In IP Deal
Gilead's ex-general counsel testified Tuesday in a "pay for delay" antitrust trial over its HIV drug patent deal with Teva, saying he never calculated a dollar value for the royalty-free license Gilead gave Teva, which ultimately gave Teva six months on the generics market ahead of competitors.
-
June 05, 2023
Ex-Gilead VP Says Execs Gamed Out Truvada Generic Date
A former Gilead executive testifying Monday in an antitrust trial over claims Gilead and Teva illegally delayed generic versions of its blockbuster HIV drugs until 2020 told jurors that before the pharmaceutical makers' deal, Gilead executives discussed the possibility that generic competition for Truvada could come as early as 2017.
-
May 30, 2023
Teva's Drug IP Deal With Gilead Not Pay To Delay, Jurors Hear
Teva's counsel defended the generic-drug maker Tuesday during opening statements in a California trial over claims it reached an anticompetitive deal with Gilead over two HIV medications, saying it settled a patent suit brought by Gilead because it risked losing, not to score an illegal "pay for delay" deal.
-
May 25, 2023
Gilead, Teva Ink 11th-Hour HIV Antitrust Deal With Pharmacies
With openings set to begin Thursday in an antitrust trial over claims Gilead and Teva illegally inflated HIV drug prices, the two drugmakers struck a last-minute deal with major pharmacies, and Gilead settled with direct purchasers — leaving indirect purchasers and others to take their claims to a California federal jury.
-
May 24, 2023
Jurors Weren't Barred Over Race, Gilead Antitrust Judge Says
A California federal judge overseeing an antitrust trial over claims that Gilead and Teva inflated HIV drug prices has rebuffed the pharmaceutical giants' Batson challenge alleging that the plaintiffs had improperly sought to exclude Asian jurors, noting that several Asian Pacific Islanders were picked for the jury.
-
May 23, 2023
HIV Drug Antitrust Trial 'Leaving The Station,' Judge Says
A California federal judge who has pressed for a settlement in a sprawling litigation over claims Gilead and Teva inflated HIV drug prices told the parties on Tuesday that the trial would go forward on Wednesday, saying, "The train is leaving the station."
-
May 10, 2023
Lack Of HIV Drug Deal Before Trial Shocks Antitrust Judge
A California federal judge on Wednesday urged parties to settle in the sprawling certified consumer antitrust class action alleging that Gilead, Janssen and Teva inflated HIV drug prices, saying that trying the case has "huge risks" and "Frankly, I'm not only disappointed, I'm astounded" the parties had not yet settled.